JO2031B1 - 5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine - Google Patents
5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridineInfo
- Publication number
- JO2031B1 JO2031B1 JO19982031A JOP19982031A JO2031B1 JO 2031 B1 JO2031 B1 JO 2031B1 JO 19982031 A JO19982031 A JO 19982031A JO P19982031 A JOP19982031 A JO P19982031A JO 2031 B1 JO2031 B1 JO 2031B1
- Authority
- JO
- Jordan
- Prior art keywords
- tetrahydropyridine
- tetrazol
- ethyl
- methyl
- acid addition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to a maleate acid addition salt of 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine, pharmaceutical compositions containing the acid addition salt and the use thereof for the treatment of disorders caused by a malfunction of the acetylcholine (AcCh) or muscarinic system.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK78197 | 1997-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO2031B1 true JO2031B1 (en) | 1999-05-15 |
Family
ID=8097489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JO19982031A JO2031B1 (en) | 1997-07-01 | 1998-06-25 | 5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP0994869A1 (en) |
JP (1) | JP2002507215A (en) |
KR (1) | KR20010014297A (en) |
CN (1) | CN1261361A (en) |
AR (1) | AR013096A1 (en) |
AU (1) | AU735751B2 (en) |
BG (1) | BG103933A (en) |
BR (1) | BR9810331A (en) |
CA (1) | CA2293324A1 (en) |
CO (1) | CO4940483A1 (en) |
EA (1) | EA200000081A1 (en) |
HU (1) | HUP0002876A2 (en) |
IL (1) | IL133093A0 (en) |
IS (1) | IS5278A (en) |
JO (1) | JO2031B1 (en) |
MA (1) | MA25138A1 (en) |
NO (1) | NO996580D0 (en) |
PE (1) | PE116099A1 (en) |
PL (1) | PL337184A1 (en) |
SK (1) | SK187399A3 (en) |
TN (1) | TNSN98120A1 (en) |
TR (1) | TR199903283T2 (en) |
UY (2) | UY25069A1 (en) |
WO (1) | WO1999001448A1 (en) |
ZA (1) | ZA985498B (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8714789D0 (en) * | 1987-06-24 | 1987-07-29 | Lundbeck & Co As H | Heterocyclic compounds |
JPH11514654A (en) * | 1995-11-06 | 1999-12-14 | ハー・ルンドベック・アクチェゼルスカベット | How to treat brain injury due to trauma |
-
1998
- 1998-06-18 AR ARP980102925A patent/AR013096A1/en not_active Application Discontinuation
- 1998-06-24 ZA ZA985498A patent/ZA985498B/en unknown
- 1998-06-25 JO JO19982031A patent/JO2031B1/en active
- 1998-06-25 PE PE1998000563A patent/PE116099A1/en not_active Application Discontinuation
- 1998-06-26 CO CO98036576A patent/CO4940483A1/en unknown
- 1998-06-29 UY UY25069A patent/UY25069A1/en not_active Application Discontinuation
- 1998-06-30 TN TNTNSN98120A patent/TNSN98120A1/en unknown
- 1998-07-01 AU AU81020/98A patent/AU735751B2/en not_active Ceased
- 1998-07-01 WO PCT/DK1998/000294 patent/WO1999001448A1/en not_active Application Discontinuation
- 1998-07-01 CN CN98806497A patent/CN1261361A/en active Pending
- 1998-07-01 PL PL98337184A patent/PL337184A1/en unknown
- 1998-07-01 IL IL13309398A patent/IL133093A0/en unknown
- 1998-07-01 KR KR1019997012429A patent/KR20010014297A/en not_active Application Discontinuation
- 1998-07-01 BR BR9810331-8A patent/BR9810331A/en not_active Application Discontinuation
- 1998-07-01 EP EP98930655A patent/EP0994869A1/en not_active Withdrawn
- 1998-07-01 CA CA002293324A patent/CA2293324A1/en not_active Abandoned
- 1998-07-01 SK SK1873-99A patent/SK187399A3/en unknown
- 1998-07-01 HU HU0002876A patent/HUP0002876A2/en unknown
- 1998-07-01 JP JP50616699A patent/JP2002507215A/en active Pending
- 1998-07-01 TR TR1999/03283T patent/TR199903283T2/en unknown
- 1998-07-01 EA EA200000081A patent/EA200000081A1/en unknown
- 1998-07-01 MA MA25155A patent/MA25138A1/en unknown
- 1998-09-10 UY UY25177A patent/UY25177A1/en not_active Application Discontinuation
-
1999
- 1999-11-30 IS IS5278A patent/IS5278A/en unknown
- 1999-11-30 BG BG103933A patent/BG103933A/en unknown
- 1999-12-30 NO NO996580A patent/NO996580D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200000081A1 (en) | 2000-08-28 |
TNSN98120A1 (en) | 2005-03-15 |
AU8102098A (en) | 1999-01-25 |
PL337184A1 (en) | 2000-08-14 |
HUP0002876A2 (en) | 2001-06-28 |
MA25138A1 (en) | 2001-04-02 |
WO1999001448A1 (en) | 1999-01-14 |
IS5278A (en) | 1999-11-30 |
AR013096A1 (en) | 2000-12-13 |
NO996580L (en) | 1999-12-30 |
UY25069A1 (en) | 1998-12-21 |
ZA985498B (en) | 1999-01-20 |
KR20010014297A (en) | 2001-02-26 |
CO4940483A1 (en) | 2000-07-24 |
SK187399A3 (en) | 2000-06-12 |
NO996580D0 (en) | 1999-12-30 |
BR9810331A (en) | 2000-09-05 |
EP0994869A1 (en) | 2000-04-26 |
TR199903283T2 (en) | 2000-06-21 |
CA2293324A1 (en) | 1999-01-14 |
UY25177A1 (en) | 2000-12-29 |
BG103933A (en) | 2000-07-31 |
IL133093A0 (en) | 2001-03-19 |
CN1261361A (en) | 2000-07-26 |
PE116099A1 (en) | 1999-11-23 |
AU735751B2 (en) | 2001-07-12 |
JP2002507215A (en) | 2002-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2198238A1 (en) | Piperidine derivatives as neurokinin antagonists | |
EP0896533A4 (en) | Pentafluorobenzenesulfonamides and analogs | |
WO2000047568A3 (en) | 1,2-benzothiazepines for the treatment of hyperlipidemic diseases | |
GEP20043303B (en) | Polycycloalkylpurines as Adenosine Receptor Antagonists | |
BG103297A (en) | Aralkyl and aralkyliden heterocyclic lactams and imides | |
NZ329627A (en) | 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones | |
SI0725779T1 (en) | ||
MX9605741A (en) | (r)-(-)-2-{n-[4-(1,1-dioxide-3-oxo-2,3-dihydro-benzisotiazole-2-yl)-buty l]-aminomethyl}-cromane crystalline chlorhydrate. | |
CA2090220A1 (en) | Treatment of non-inflammatory and non-infectious bowel disorders | |
PL374325A1 (en) | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof | |
HUT71550A (en) | Pharmaceutical agents containing quinuclidine, piperidine or azanorbornane derivatives for treatment of emesis | |
MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
DZ2141A1 (en) | Intermediate processes for the preparation of 1-benzyl-4- (5,6-dimethoxy-1-indanone) -2-yi) methylpiperidine. | |
WO2001010408A3 (en) | Aqueous pharmaceutical composition containing moxifloxacin or salts thereof | |
CA2235747A1 (en) | Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis | |
WO1999006388A3 (en) | Pharmaceutical compounds isolated from aristolochia taliscana | |
WO1996022305A3 (en) | Modified peptides | |
CA2168131A1 (en) | Tetrahydro-1h-benzazepinones containing acid surrogates | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
BR9811821A (en) | 2-acylaminopropanamines as tachykinin receptor antagonists | |
WO1996031208A3 (en) | Use of substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders | |
NZ220195A (en) | 2-pyridyl-penem derivatives and pharmaceutical compositions | |
JO2031B1 (en) | 5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine | |
WO2000033788A3 (en) | Substituted nitrogen heterocyclic compounds and therapeutic uses thereof | |
CA2309439A1 (en) | 3-(3-hydroxyphenyl)-3-amino-propionamide derivatives |